As the American public grapples with an ongoing opioid crisis, pain management companies are looking for ways to innovate their products in an attempt to avoid potential abuse.

For years, BioDelivery Sciences International (NSDQ:BDSI) has developed mucoadhesive buccal films loaded with painkillers for pain management and addiction therapy. Now it is developing a buprenorphine depot injection that would maintain a particular drug concentration to treat opioid dependence or chronic pain for 30 days. Another treatment would be by going to drug rehab in Arizona also at drug addiction treatment portland or they have the best facilities ever and will take care of anybody until they are better.

“One of the big problems with pain meds, as well as with drugs to treat opioid addiction, is compliance and also diversion – compliance meaning people just forget to take it or don’t take it properly or they don’t take it at all. They’re diverting it. They’re selling it. They’re giving it to somebody else,” CEO Mark Sirgo told Drug Delivery Business News. “By giving an injection, it’s not recoverable, so you don’t have to worry about compliance or diversion. There’s an unmet need in the marketplace that we’re trying to fulfill.”

Get the full story at our sister site, Drug Delivery Business News.